The 3rd Novel IVD Congress China

In the medical industry, IVD is an important segment which has a broad market and a rapid development. As grading clinics is accelerated in 2017, clinical testing products and third party services will be extremely important. Among the IVD sub- sectors, microbiology and prenatal diagnosis are two major areas of rapid development. According to statistics, in the next five years, the increase in the use of emerging viral and microbial nucleic acid testing will bring IVD products to market growth of 10% to 15%. A series of favorable policies, such as the second child landing is also a great opportunity for reproductive and deficiency disease diagnosis market.

However, regulatory policies and market development direction, the integration of public and private resources, are common confusions for the IVD industry. In the field of microbiology and infectious diseases, how to improve the efficiency of microbial test, expand the clinical application and development, is not to be overlooked. Meanwhile, from pre pregnancy to prenatal and postpartum, the need for accurate and standardized diagnosis, as well as timely intervention and early research on birth defects and common genetic diseases has become an important challenge.

Therefore, facing these challenges, the 3rd Novel IVD Congress China will provide you with IVD industry trends of advanced technology, innovative development of independent laboratory and clinical laboratory, rapid microbial clinical identification, diagnosis and clinical application of birth defects, and common genetic diseases.